Effect of dapagliflozin treatment on epicardial fat attenuation in patients with coronary heart disease and type 2 diabetes mellitus
10.13699/j.cnki.1001-6821.2024.09.001
- VernacularTitle:达格列净对冠心病合并2型糖尿病患者心外膜脂肪衰减值的影响
- Author:
Mei LIU
1
;
Xue-Ru FENG
;
Mei-Lin LIU
Author Information
1. 北京大学第一医院老年病内科,北京 100034
- Keywords:
sodium-glucose cotransporter 2 inhibitor;
dapagliflozin;
coronary heart disease;
type 2 diabetes mellitus;
epicardial adipose tissue
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(9):1243-1247
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the effect of dapagliflozin on epicardial fat attenuation(EFat)in patients with coronary heart disease and type 2 diabetes.Methods The patients with coronary heart disease and type 2 diabetes in our hospital were retrospectively collected.The patients were grouped into treatment group and control group.The treatment group was newly treated with dapagliflozin on the basis of the original treatment.The control group maintained the original antidiabetic drugs without using dapagliflozin.After median follow-up of thirteen months,the clinical characteristics,including body mass index(BMI),fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c),triglycerides,total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),and EFat between the two groups were compared.Results A total of 235 patients were collected,of which 205 cases completed follow-up.There were 111 cases in the treatment group and 94 cases in the control group.The BMI,FBG and HbA1c of patients in the treatment group significantly decreased compared to those before therapy,while HDL-C significantly increased.The EFat of patients in the treatment group significantly decreased compared to baseline[(-96.48±14.71)HU vs(-88.59±10.60)HU,P＜0.05].Pearson correlation analysis showed a negative correlation between changes in EFat and changes in HDL-C in patients in the treatment group(r=-0.188,P＜0.05).Conclusion Dapagliflozin can reduce the epicardial fat attenuation in patients with coronary heart disease and type 2 diabetes.
